Loading organizations...
§ Private Profile · Novara, Piemonte, Italy
Italian biotech company developing novel therapies for rare and autoimmune disorders, focused on calcium-related genetic diseases.
ChemiCare is an Italy-based biotechnology company that develops novel therapeutic molecules and orphan drugs for the treatment of rare genetic and autoimmune disorders. The organization leverages its specialized expertise in medicinal chemistry and pharmacology to create targeted therapies focused primarily on complex calcium-related genetic diseases. Its primary therapeutic candidate, a proprietary molecule designated as CIC-39, is currently advancing toward clinical trials to address severe medical conditions such as Duchenne muscular dystrophy and various autoimmune syndromes. To support its ongoing clinical development pipeline and broader research operations, the enterprise recently completed a €2.5 million seed financing round. This equity funding was backed by a syndicate of institutional investors and regional development funds, including CDP Venture Capital, Bio4Dreams, Bridge4Pharma, and FinPiemonte. Operating as a venture-backed entity, the company was established by co-founders Beatrice Riva and Tracey Pirali.
ChemiCare has raised $2.9M across 1 funding round.
ChemiCare has raised $2.9M in total across 1 funding round.
ChemiCare has raised $2.9M across 1 funding round. Most recently, it raised $2.9M Seed in December 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 19, 2025 | $2.9M Seed | Mario Alparone | Bio4dreams, Bridge4pharma, CDP Venture Capital | Announced |
ChemiCare has raised $2.9M in total across 1 funding round.
ChemiCare's investors include Mario Alparone, Bio4Dreams, Bridge4Pharma, CDP Venture Capital.